Clinical trials: Group 3 Pulmonary Hypertension, active
Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
A Phase 3 Study of Extended-release Tacrolimus in Subjects With Pulmonary Arterial Hypertension and Functional Limitations
This study evaluates the effects of VI-0106 (an extended-release formulation of tacrolimus) in participants with pulmonary arterial hypertension (PAH) who continue to have functional limitations despite being on optimized…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Arterial Hypertension PAH
- Trial name
- TRANSCEND (NCT07612657)
- Testing
- VI-0106
- Volunteers
- 300 people
- Sponsor
- VIVUS LLC
Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension
DeciPHer-ILD: A Real-world Patient Registry in Group 3 Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
This is a prospective, real world, multicenter, registry of patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and interstitial lung disease (ILD).
- Conditions
- Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
- Trial name
- NCT06388421
- Testing
- Prospective study assessments
- Where
- 71 sites in United States, Puerto Rico
- Volunteers
- 900 people
- Sponsor
- United Therapeutics
Pulmonary Hypertension Associated With HFpEF
LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2
The purpose of this study is to assess the efficacy and safety of the study drug, levosimendan (given orally), compared to placebo in participants with pulmonary hypertension with heart failure with preserved left ventricular…
- Trial name
- LEVEL-2 (NCT07288398)
- Testing
- TNX-103
- Where
- 140 sites in United States, Argentina and 13 more
- Volunteers
- 540 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Trial of "APL-9796'' in Adults With Pulmonary Hypertension
The AP13CP02 study is a phase 2, open-label, dose escalation trial to determine how safe and tolerable multiple subcutaneous (SC) injections of APL-9796 are for patients with PH.
- Trial name
- ViTAL-PH (NCT06846554)
- Testing
- APL-9796
- Where
- 6 sites in United Kingdom
- Volunteers
- 48 people
- Sponsor
- Apollo Therapeutics Ltd
Interstitial Lung Disease, Precapillar Pulmonary Hypertension
Exploration of Metabolome in Patients With Interstitial Lung Disease and Pulmonary Hypertension With or Without Specific Pulmonary Hypertension Treatment
Fibrosing interstitial lung diseases (FILDs) encompass a group of rare diseases characterized by progressive pulmonary fibrosis leading to respiratory failure.
- Trial name
- BREATH-TPT (NCT07254338)
- Testing
- Blood sampling for metabolomic profiling, Urine sampling for metabolomic profiling
- Where
- France
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Pulmonary Hypertension
TEPH: Telaglenastat Efficacy in Pulmonary Hypertension
The research study is being conducted to evaluate the effectiveness of a drug called Telaglenastat in adults diagnosed with Pulmonary Hypertension (PH).
- Trial name
- TEPH (NCT07223528)
- Testing
- Telaglenastat
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Chan, Stephen, MD, PhD
Pulmonary Hypertension, Interstitial Lung Disease
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP versus placebo on exercise capacity in adults with PH-ILD.
- Trial name
- PALM-ILD (NCT07179380)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 186 sites in United States, Argentina and 28 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Hypertension
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
This study will evaluate the efficacy of TNX-103 (oral levosimendan) compared with placebo in subjects with PH-HFpEF as measured by the change in 6-Minute Walk Distance (6 MWD; Day 1 to Week 12).
- Trial name
- LEVEL (NCT05983250)
- Testing
- TNX-103
- Where
- 42 sites in United States, Canada
- Volunteers
- 230 people
- Sponsor
- Tenax Therapeutics, Inc.
Pulmonary Arterial Hypertension
A Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Arterial Hypertension (PAH)
The primary objective of this study is to evaluate the effect of 24-weeks of once daily treatment with TPIP compared with placebo on exercise capacity in adults with PAH.
- Trial name
- PALM-PAH (NCT07481981)
- Testing
- Treprostinil Palmitil Inhalation Powder
- Where
- 39 sites in United States, Argentina and 6 more
- Volunteers
- 344 people
- Sponsor
- Insmed Incorporated
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3)
Nailfold Capillaroscopy in PH
Pulmonary hypertension (PH) is an uncommon condition and can often be difficult to diagnose. It means elevated blood pressure in the lungs which can rapidly lead to failure of the right side of the heart and is ultimately fatal.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3), Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT07768644
- Testing
- Standard of Care therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Glasgow
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics
Interstitial Lung Disease, COPD
Pulmonary Hypertension SOLAR
The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI).
- Conditions
- Interstitial Lung Disease, COPD, Pulmonary Arterial Hypertension
- Trial name
- PH SOLAR (NCT04778046)
- Testing
- Hyperpolarized 129Xe
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Bastiaan Driehuys
Pulmonary Hypertension Due to Lung Disease (Disorder)
A Phase 3 Study to Evaluate the Safety and Efficacy L606 in Participants With PH-ILD
The purpose of this study is to find out if L606 is safe and if it helps people with high blood pressure in the lungs (pulmonary hypertension) caused by interstitial lung disease (PH-ILD, WHO Group 3).
- Trial name
- Re-Spire (NCT07285655)
- Testing
- L606
- Where
- 44 sites in United States, Australia and 10 more
- Volunteers
- 344 people
- Sponsor
- Liquidia Technologies, Inc.
Pulmnary Hypertension, COPD
Hemodynamic Effects of Inhaled Iloprost in PH-COPD (HOLLYWOOD)
Study Title: A Clinical Study of Inhaled Iloprost for the Treatment of Pulmonary Hypertension in Patients With Chronic Obstructive Pulmonary Disease (HOLLYWOOD) The goal of this clinical study is to learn if the inhaled drug…
- Conditions
- Pulmnary Hypertension, COPD, Pulmonary Hypertension Secondary to Lung Disease and/or Hypoxia
- Trial name
- HOLLYWOOD (NCT07263958)
- Testing
- Iloprost is a synthetic molecule with pharmacological action
- Volunteers
- 15 people
- Sponsor
- University of Sao Paulo General Hospital
Group 3 Pulmonary Hypertension
Study to Evaluate Safety and Efficacy of Mirivadelgat in PH-ILD (Windward)
The goal of this clinical trial is to see if mirivadelgat will work in participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD). It will also learn about the safety of mirivadelgat.
- Trial name
- WINDWARD (NCT06475781)
- Testing
- Mirivadelgat
- Where
- 11 sites in Bosnia and Herzegovina, Taiwan
- Volunteers
- 126 people
- Sponsor
- Foresee Pharmaceuticals Co., Ltd.
Pulmonary Hypertension
The Role of miRNA in Group 3 Pulmonary Hypertension
This study recognizes the substantial value of lung tissue obtained from explanted lungs for fundamental research purposes.By analyzing pulmonary tissue affected by pulmonary hypertension, it is possible to discover shared…
- Trial name
- miRNA-GR3PH (NCT06714136)
- Where
- Italy
- Volunteers
- 27 people
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna
Pulmonary Arterial Hypertension
Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension
The purpose of this study is to demonstrate superiority of macitentan 75 milligrams (mg) in prolonging the time to the first clinical events committee (CEC)-adjudicated morbidity or mortality (M/M) event in participants with…
- Trial name
- UNISUS (NCT04273945)
- Testing
- Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg
- Where
- 274 sites in United States, Argentina and 40 more
- Volunteers
- 935 people
- Sponsor
- Actelion